Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathy
- Conditions
- Taxane-induced neuropathy.
- Registration Number
- IRCT20090613002027N21
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
People aged 18 years and older
Patients with taxane-induced peripheral neuropathy
Existence of moderate to severe neuropathic pain with PI-NRS score =4
Normal baseline ECG
Patients with a history of neurological diseases such as hereditary or acquired neuropathies
Patients with neuropathic pain due to conditions such as post-herpes neuralgia, uncontrolled diabetes with neuropathy, trigeminal neuralgia, spinal cord injury or other neurological diseases, known vitamin B12 deficiency, amyloidosis, neuromuscular diseases and connective tissue diseases
Creatinine clearance less than 30 ml / min
Severe liver failure
History of allergy to lacosamide or duloxetine
History of duloxetine or lacosamide use
Evidence of severe systemic disease
patients with epilepsy
Drugs that interact with the study drugs including tricyclic antidepressants (TCAs), norepinephrine-specific serotonin reuptake inhibitors (SNRIs), and sodium channel blockers in the past three months
Use of monoamine oxidase inhibitors (MAOIs) in the last fourteen days or simultaneously
Drugs that interact with the study drugs including atazanavir, siponimod, carbamazepine, phenobarbital, phenytoin, amiodarone, sotalol, antiarrhythmic drugs that increase QT interval, including class IA and IC, beta-blockers and non-dihydropyridine calcium channel blockers, lidocaine, and mexiletine
Pregnant or lactating women
Dissatisfaction with participating in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method